Anbio BiotechnologyNNNN -12.41%24 Net Current Asset Value is $0.69 as of Dec. 2025, which is 98% below its 10-year median of 43.58. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 569 Medical Devices & Instruments companies, Anbio Biotechnology ranks worse than 82.43% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Anbio Biotechnology's net current asset value per share for the quarter that ended in Dec. 2025 was $0.69.
The historical rank and industry rank for Anbio Biotechnology's Net Current Asset Value or its related term are showing as below:
NNNN'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 12.96 Med: 43.58 Max: 43.58
Current: 13.61
During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Anbio Biotechnology was 43.58. The lowest was 12.96. And the median was 43.58.
NNNN's Price-to-Net-Current-Asset-Value is ranked worse than 82.43% of 569
companies
in the Medical Devices & Instruments industry
Industry Median: 4.99
vs NNNN: 13.61
Anbio Biotechnology (NAS:NNNN) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Anbio Biotechnology Net Current Asset Value Related Terms
Anbio Biotechnology Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNNN vs ANGO, OSUR, UTMD: Net Current Asset Value Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.69 mean?
Anbio Biotechnology (NNNN) has a Net Current Asset Value of $0.69 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Anbio Biotechnology and its competitors. This is 98% below median its historical median of 43.58. Over the past decade, Anbio Biotechnology's Net Current Asset Value has ranged from 12.96 to 43.58. According to the industry distribution chart, Anbio Biotechnology ranks #469 out of 569 companies in the Medical Devices & Instruments industry, placing it in the top 82.4%.
Is Anbio Biotechnology's Net Current Asset Value too high?
Anbio Biotechnology's current Net Current Asset Value of $0.69 is 98% below median its 10-year median of 43.58. Over the past 10 years, this metric has ranged from a low of 12.96 to a high of 43.58. The Medical Devices & Instruments industry median Net Current Asset Value is 4.99. Anbio Biotechnology's value of $0.69 is 86.2% below this industry median. Based on the distribution chart, Anbio Biotechnology ranks #469 out of 569 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Net Current Asset Value compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #469 out of 569 companies for Net Current Asset Value. This places Anbio Biotechnology in the lower half of its industry. The industry median Net Current Asset Value is 4.99. Anbio Biotechnology's value of $0.69 is 86.2% below this benchmark. Historically, Anbio Biotechnology's own Net Current Asset Value has ranged from 12.96 to 43.58 over the past decade. While the company's 10-year median is 43.58 vs. the industry median of 4.99, Anbio Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.99, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current Net Current Asset Value of $0.69 is 86.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current Net Current Asset Value is $0.69, which is 98% below median its own 10-year median of 43.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Net Current Asset Value of $0.69. The current Net Current Asset Value is $0.69, which is 98% below median its 10-year median of 43.58 and 86.2% below the Medical Devices & Instruments industry median of 4.99. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Net Current Asset Value is $0.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
